Europe Cancer Cachexia Market Size, Share, Industry, Forecast and outlook (2024-2031)

Europe Cancer Cachexia Market is segmented By Therapeutics (Corticosteroids, Cannabinoids (Dronabinol), Anabolic Steroids, Cytokine Inhibitors, Others), By Mechanism (Appetite Stimulator, Weight Loss Stabilizers, Others), By Distribution Channel (Hospital Stores, Retail Pharmacy Stores, Online Pharmacy) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

The Europe cancer cachexia market size was valued at US$ 618.75 million in 2022 and is estimated to reach US$ 897.58 million by 2030, growing at a CAGR of 4.8% during the forecast period (2024-2031). Cancer cachexia, is a wasting syndrome which is generally diagnosed in the cancer patients.

Cancer cachexia often develops along with anorexia and progressive muscle and tissue degeneration. Cancer cachexia is manifested by significant weight loss, anorexia, anemia and asthenia. Other cachexia symptoms include drastic weight loss, fatigue and severe weakness. It reduces both the quality and length of life of the cancer patients. Besides cancer, cachexia is also seen in HIV/AIDS, heart failure, kidney failure and multiple sclerosis. Drugs such as Medroxyprogesterone Acetate (MPA) and Megestrol Acetate (MA) are approved in Europe for treatment of cancer cachexia.

Market Summary

For more details on this report - Request for Sample

Market Dynamics

The Europe cancer cachexia market growth is driven by increasing incidences of cancer cachexia, government funding and research initiatives, advancements in technology, growing use of cancer cachexia in targeted therapy, the growing number of pharmaceutical companies in Europe and the increasing number of clinical trials and research activities in Europe.

Rising incidences of cancer cachexia and increasing clinical trials drives the market growth      

Cancer is a global health concern, it is rapidly increasing across the globe. Due to increase in cancer rates, cancer cachexia is also seen to be increasing at a steady rate. In August 2022, a study published by the Baylor University, Texas,U.S. stated that globally several patients with advanced cancers experience cachexia. Cachexia is between 70% to 90% more likely to occur in people with liver, lung, or gastrointestinal malignancies. Although cachexia is not common in people with primary brain tumours, it is between 20 to 80% more likely in people with cancers like lung, breast, and skin that frequently cause secondary brain metastases. Thus, the increasing rates of cancer cachexia is is expected to drive growth in the cancer cachexia market over the forecast period.

In addition, various major companies in the market are conducting clinical trials for a curative treatment that can prominently treat cancer cachexia. For instance, in January 23, 2023, India-based pharmaceutical company Mankind Pharma announced that they have invested in a UK-based company Actimed for the development of the S-pindolol for the treatment of cancer cachexia. Actimed is currently planning the next stage of clinial trail that is phase 2b/3 studies in cancer cachexia. 

The high cost of cancer cachexia treatment options will hamper the growth of the market   

Cancer cachexia is a less explored syndrome which doesn’t have sufficient treatment option. There are only two drugs that European Medicines Agency (EMA) has approved for the treatment of cancer cachexia. Cancer treatments are generally expensive and cancer cachexia treatment further increases the treatmnet cost which is anticipated to hamper the market. Huge investments are also required for the research and development for the cancer cachexia drugs. Further, the high cost of cancer treatment and other supportive treatments itself hinders the growth of cancer cachexia treatment drugs. Therefore, due to high cost of cancer cachexia treatment is expected to hamper cancer cachexia market in the forecast period. 

COVID-19 Impact on Market

The COVID-19 pandemic has had significant effects on the Europe cancer cachexia market. The COVID-19 pandemic has significantly impacted research and development activities in Europe. In Europe all the major countries were hit by the huge wave of covid-19 during 2020-2021, during this time all the healthcare facilities were facing interuption in the cancer care services. Due to this disruption in the healthcare facilities the treatment of cancer along with cancer cachexia was highly impacted. All cancer treatments were delayed because of the prioritized treatment of covid-19 patients. 

Cancer affects millions of people across the globe and cancer patients are more vulnerable to get affected by the covid-19 infection, and also being at risk for life-threatening illnesses and having their regular medical care interrupted. As a result, oncologists have had a difficult time finding a balance between providing patients with high-quality, continuous, uninterrupted cancer care and reducing their risk of exposure while receiving treatment. The pandemic's detrimental effects are probably going to be more pronounced in low- and middle-income countries, where there are fewer resources, weak infrastructure, health care providers and organised care teams are scarce, medical supplies and personal protective equipment (PPE) are scarce, and access to technology is limited, making it difficult to deliver critical care. Therefore, the covid-19 has negatively impacted the cancer cachexia market.

Market Segment Analysis

The Corticosteriods segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

Corticosteriods segment is expected to account for the largest market share in the Europe cancer cachexia market. The major reason for development of cancer cachexia is loss of appetite and loss of energy. Thus, the use of appetite stimulant is the majorly used medication for cancer cachexia. According to the data publihsed in the National Center for Biotechnology Information (NCBI), various studies revealed that the use of corticostersoids significantly improved the symptoms of anorexia, asthenia, and cancer-related pain.

Corticosteriods along with Megestrol Acetate (MA) among the other classes of drugs are widely used to treat cancer cachexia. Further, in Europe, megestrol acetate and medroxyprogesterone acetate are approved for the treatment of cancer- and AIDS-related cachexia, and they are regarded as the most efficient therapy options for cancer caxhexia.

Market Geographical Share

UK region holds the largest market share of the Europe cancer cachexia market 

The U.K dominates the market for cancer cachexia and is expected to show a growth over the forecast period. The Europe cancer cachexia market is driven by the presence of prominent research centers and Universities, the rising number of research investments and fundings, and the presence of many pharmaceutical and biotechnology key players in the United Kingdom region. 

For instance, in 2020, the National Cancer Institute (NCI) and Cancer Research UK, partnered together to launch the Cancer Grand Challenges program. This program focuses on provide various fundings to different research institutes to develop new treatment options for cancer cachexia. 

Further, in June 2022, cancer researchers at the Cancer Research UK Beatson Institute and the University of Glasgow received $1.9 million to investigate the causes of a debilitating wasting disease that several cancer patients suffer in the later stages of cancer.

Companies and Competitive Landscape 

The Europe cancer cachexia market is a highly competitive market due to presence of major pharmaceutical companies. Some of the key players which are contributing to the growth of the market are Actimed Therapeutics Ltd., Aphios Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Helsinn Group, Merck & Co. Inc., Fresenius Kabi AG, NGM Biopharmaceuticals, Aveo Oncology, AAVogen Inc. among others. The major players are adopting several growth strategies, such as clinical trials, acquisitions, and collaborations, contributing to the growth of the Europe cancer cachexia market. 

For instance, in March 2021, NGM Biopharmaceuticals, Inc., a biotechnology company focused on developing novel and innovative therapeutics for cancer patients, dosed the first patient in an expansion of its ongoing Phase 1b proof-of-concept study of NGM120 in patients with metastatic pancreatic cancer. NGM120 is an antagonistic antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling.

Bristol-Myers Squibb Company

Overview: 

Bristol-Myers Squibb Company is a global pharmaceutical company which discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Currently, the company is focusing on branded specialty drugs. Bristol-Myers Squibb has built a strong portfolio of drugs and a robust pipeline.

Product Portfolio:

MEGACE:  MEGACE (megestrol acetate) Oral Suspension contains megestrol acetate, a synthetic derivative of the steroid hormone, progesterone. It contains 40 mg of micronized megestrol acetate per mL.

The Europe cancer cachexia market report would provide access to approximately 58 market data tables, 54 figures, and in the range of 200 (approximate) pages.